JP7846086B2 - Ikaros又はaiolosによって媒介される障害に対する有利な治療法 - Google Patents

Ikaros又はaiolosによって媒介される障害に対する有利な治療法

Info

Publication number
JP7846086B2
JP7846086B2 JP2023507879A JP2023507879A JP7846086B2 JP 7846086 B2 JP7846086 B2 JP 7846086B2 JP 2023507879 A JP2023507879 A JP 2023507879A JP 2023507879 A JP2023507879 A JP 2023507879A JP 7846086 B2 JP7846086 B2 JP 7846086B2
Authority
JP
Japan
Prior art keywords
compound
pharmaceutical composition
administered
composition according
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023507879A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023538520A (ja
JP2023538520A5 (cg-RX-API-DMAC7.html
Inventor
デイビッド プロイア
ジェームズ エー. ヘンダーソン
ミンシェン フー
アンドリュー チャールズ グッド
アンドリュー ジェイ. フィリップス
Original Assignee
シーフォー セラピューティクス, インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シーフォー セラピューティクス, インコーポレイテッド filed Critical シーフォー セラピューティクス, インコーポレイテッド
Publication of JP2023538520A publication Critical patent/JP2023538520A/ja
Publication of JP2023538520A5 publication Critical patent/JP2023538520A5/ja
Priority to JP2026060896A priority Critical patent/JP2026117027A/ja
Application granted granted Critical
Publication of JP7846086B2 publication Critical patent/JP7846086B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/499—Spiro-condensed pyrazines or piperazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2023507879A 2020-08-07 2021-08-06 Ikaros又はaiolosによって媒介される障害に対する有利な治療法 Active JP7846086B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026060896A JP2026117027A (ja) 2020-08-07 2026-04-02 Ikaros又はaiolosによって媒介される障害に対する有利な治療法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063063011P 2020-08-07 2020-08-07
US63/063,011 2020-08-07
US202163173160P 2021-04-09 2021-04-09
US63/173,160 2021-04-09
US202163212463P 2021-06-18 2021-06-18
US63/212,463 2021-06-18
PCT/US2021/045000 WO2022032132A1 (en) 2020-08-07 2021-08-06 Advantageous therapies for disorders mediated by ikaros or aiolos

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026060896A Division JP2026117027A (ja) 2020-08-07 2026-04-02 Ikaros又はaiolosによって媒介される障害に対する有利な治療法

Publications (3)

Publication Number Publication Date
JP2023538520A JP2023538520A (ja) 2023-09-08
JP2023538520A5 JP2023538520A5 (cg-RX-API-DMAC7.html) 2024-08-15
JP7846086B2 true JP7846086B2 (ja) 2026-04-14

Family

ID=80118544

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023507879A Active JP7846086B2 (ja) 2020-08-07 2021-08-06 Ikaros又はaiolosによって媒介される障害に対する有利な治療法
JP2026060896A Pending JP2026117027A (ja) 2020-08-07 2026-04-02 Ikaros又はaiolosによって媒介される障害に対する有利な治療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026060896A Pending JP2026117027A (ja) 2020-08-07 2026-04-02 Ikaros又はaiolosによって媒介される障害に対する有利な治療法

Country Status (12)

Country Link
US (1) US20230190760A1 (cg-RX-API-DMAC7.html)
EP (1) EP4192450A4 (cg-RX-API-DMAC7.html)
JP (2) JP7846086B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230049678A (cg-RX-API-DMAC7.html)
CN (1) CN116194438B (cg-RX-API-DMAC7.html)
AU (1) AU2021322285B2 (cg-RX-API-DMAC7.html)
BR (1) BR112023002225A2 (cg-RX-API-DMAC7.html)
CA (1) CA3173658A1 (cg-RX-API-DMAC7.html)
IL (1) IL300373A (cg-RX-API-DMAC7.html)
MX (1) MX2023001545A (cg-RX-API-DMAC7.html)
TW (1) TWI887465B (cg-RX-API-DMAC7.html)
WO (1) WO2022032132A1 (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4717317A3 (en) 2017-06-20 2026-06-03 C4 Therapeutics, Inc. N/o-linked degrons and degronimers for protein degradation
KR102947433B1 (ko) * 2019-04-12 2026-04-06 씨4 테라퓨틱스, 인코포레이티드 이카로스 및 아이올로스의 트리시클릭 분해제
SMT202600194T1 (it) * 2019-10-21 2026-05-12 Celgene Corp Combinazione di composti di 4-amminoisoindolin-1,3-dione sostituiti e di secondi agenti attivi per l'uso nel trattamento di una condizione maligna ematologica
US11807620B2 (en) 2020-02-21 2023-11-07 Plexium, Inc. Quinazolinone compounds and related compounds
CN119823124A (zh) 2020-03-05 2025-04-15 C4医药公司 用于brd9的靶向降解的化合物
CA3194351A1 (en) * 2020-10-14 2022-04-21 Christopher G. Nasveschuk Tricyclic compounds to degrade neosubstrates for medical therapy
JP7863100B2 (ja) * 2020-10-14 2026-05-20 シーフォー セラピューティクス, インコーポレイテッド Ikzf2又はikzf4を分解する三環式リガンド
JP7807110B2 (ja) * 2021-08-27 2026-01-27 ハンチョウ グルビオ ファーマシューティカル カンパニー,リミティド イソインドリノン化合物およびその使用
JP2025505687A (ja) * 2022-02-09 2025-02-28 シーフォー セラピューティクス, インコーポレイテッド Cft7455のモルフィック形態及びその製造方法
WO2024073507A1 (en) 2022-09-28 2024-04-04 Theseus Pharmaceuticals, Inc. Macrocyclic compounds and uses thereof
WO2024193641A1 (zh) * 2023-03-21 2024-09-26 上海超阳药业有限公司 异吲哚啉衍生物和苯并吲哚衍生物及其应用
JP2026524477A (ja) 2023-06-30 2026-07-22 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Krasの分解のためのヘテロ二官能性化合物
CN122206684A (zh) 2023-06-30 2026-06-12 默克专利有限公司 用于kras蛋白降解的异双功能化合物
CN121620373A (zh) * 2024-07-26 2026-03-06 上海超阳药业有限公司 苯并吲哚衍生物的药物组合物、制备方法及用途
WO2026065268A1 (en) * 2024-09-29 2026-04-02 Biofront Ltd Novel conjugates for protein degradation, compositions comprising the same, and methods of using the same
WO2026139448A1 (en) 2024-12-23 2026-07-02 Merck Patent Gmbh Heterobifunctional compounds for the degradation of kras protein
CN120138159A (zh) * 2025-04-30 2025-06-13 徐州医科大学 Nup35基因作为胶质母细胞瘤诊断、预后及治疗靶点的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019191112A1 (en) 2018-03-26 2019-10-03 C4 Therapeutics, Inc. Cereblon binders for the degradation of ikaros
WO2019241274A1 (en) 2018-06-13 2019-12-19 Biotheryx, Inc. Aminoamide compounds

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012175481A1 (en) * 2011-06-20 2012-12-27 Institut Curie Compositions and methods for treating leukemia
CN111662226B (zh) * 2015-01-28 2022-03-18 中国科学院广州生物医药与健康研究院 一种2-氧代-1,2-二氢苯并[cd]吲哚类化合物
EP4717317A3 (en) * 2017-06-20 2026-06-03 C4 Therapeutics, Inc. N/o-linked degrons and degronimers for protein degradation
KR102947433B1 (ko) * 2019-04-12 2026-04-06 씨4 테라퓨틱스, 인코포레이티드 이카로스 및 아이올로스의 트리시클릭 분해제

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019191112A1 (en) 2018-03-26 2019-10-03 C4 Therapeutics, Inc. Cereblon binders for the degradation of ikaros
WO2019241274A1 (en) 2018-06-13 2019-12-19 Biotheryx, Inc. Aminoamide compounds

Also Published As

Publication number Publication date
CA3173658A1 (en) 2022-02-10
EP4192450A1 (en) 2023-06-14
AU2021322285A1 (en) 2023-04-13
JP2023538520A (ja) 2023-09-08
BR112023002225A2 (pt) 2023-03-07
KR20230049678A (ko) 2023-04-13
US20230190760A1 (en) 2023-06-22
TWI887465B (zh) 2025-06-21
IL300373A (en) 2023-04-01
MX2023001545A (es) 2023-05-03
JP2026117027A (ja) 2026-07-14
CN116194438A (zh) 2023-05-30
AU2021322285B2 (en) 2026-08-13
WO2022032132A1 (en) 2022-02-10
CN116194438B (zh) 2026-08-07
TW202220981A (zh) 2022-06-01
EP4192450A4 (en) 2024-08-21

Similar Documents

Publication Publication Date Title
US20230190760A1 (en) Advantageous therapies for disorders mediated by ikaros or aiolos
US20240018118A1 (en) Tricyclic compounds to degrade neosubstrates for medical therapy
JP7863100B2 (ja) Ikzf2又はikzf4を分解する三環式リガンド
JP2024523839A (ja) 突然変異体brafを分解する療法薬
BR112021000049A2 (pt) Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona e seu uso no tratamento de doenças dependentes de dedo de zinco da família ikaros 2 (ikzf2)
BR112021015672A2 (pt) Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona substituída e usos dos mesmos
WO2018005863A1 (en) Pyrimidine-based compounds for the treatment of cancer
JP2023536164A (ja) ヘテロアリール置換3-(1-オキソイソインドリン-2-イル)ピペリジン-2,6-ジオン誘導体及びその使用
US20240391912A1 (en) Morphic forms of cft7455 and methods of manufacture thereof
JP2024521791A (ja) 脳又はcnsへの癌転移を治療するためのegfrデグレーダー
JP2025540907A (ja) Ret-lddタンパク質分解誘導剤
RU2844734C1 (ru) Преимущественные терапии нарушений, опосредованных ikaros или aiolos
US20250289827A1 (en) Morphic forms of a mutant braf degrader and methods of manufacture thereof
CN118660884A (zh) Cft7455的晶型物及其制造方法
JP2025540906A (ja) Ret-lddタンパク質阻害剤
WO2025129116A1 (en) Compounds for the targeted degradation of smarca2
BR112019027967A2 (pt) forma b cristalina isolada, composição farmacêutica, método para o tratamento de um distúrbio, método de um composto ou composição, e, processo para produzir forma b cristalina.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240806

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240806

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250722

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250723

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251020

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260203

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260213

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260402

R150 Certificate of patent or registration of utility model

Ref document number: 7846086

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150